Therapix
Biosciences2023-12-14T23:29:11-05:00

Gemphire
2023-12-15T00:46:54-05:00

PhaseRx
2023-12-14T23:26:23-05:00

Cerecor, Inc.
2023-12-15T00:13:04-05:00
Viking
Therapeutics
2023-12-14T22:48:39-05:00
Site Info

Home
Contact Us
Company History

Legal

Terms and Conditions
Legal Information
Privacy Policy
Glossary
Record of Processing Activities
GDPR Rights Exercise Form

Disclosures

FINRA
SIPC
FCA
Business Continuity Plan Disclosure
Brokercheck
REGBI
StoneX Annual Disclosure
Options Disclosure Booklet

Contact Info

© 2024 Copyright Laidlaw & Company (UK) Ltd. – All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through StoneX, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).

© Copyright 2025 Laidlaw & Company (UK) Ltd. - All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).

You are now leaving Laidlaw & Company (UK) Ltd.

This link to the Private Stakes Program is provided as a service to Members, Clients and interested parties and will direct you to a third-party site independent of Laidlaw & Company (UK) Ltd.

Neither Laidlaw & Company (UK) Ltd. nor Laidlaw Private Equity, LLC own or manage the Private Stakes Program alternative investment vehicles. They are not responsible for the content of the site and do not guarantee the accuracy or completeness of any information or material contained therein.

Associated persons of Laidlaw & Company (UK) Ltd. and Laidlaw Private Equity, LLC are involved in the management and administration of each alternative investment vehicle described in the Private Stakes Program website.

Go to Top